EcoR1 Capital
EcoR1 Capital is a privately held, biotech-focused investment advisory firm founded in 2013 in San Francisco that invests across all stages of drug research and development, managing a portfolio of 60–70+ biotechnology companies for qualified investors via management and performance fees.
- Company typePrivate
- Founded2013
- HeadquartersSan Francisco, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What EcoR1 Capital does
EcoR1 Capital, LLC is a privately held, biotech-focused investment advisory firm headquartered at 357 Tehama Street, Floor 3, San Francisco. Founded in 2013 by Oleg Nodelman—previously a portfolio manager at BVF Partners—the firm invests in companies across all stages of research and development, with a portfolio spanning 60–70+ biotechnology companies across oncology, immunology, genetic diseases, cell therapy, and other therapeutic areas. Its stated approach emphasizes a "four-dimensional" vetting framework centered on management quality, scientific strength, financing rationale, and patient impact, delivered through long-term partnerships rather than short-term financial engineering.
The firm operates without a unified technology product platform; its core offering is investment capital and strategic partnership provided to biotech entrepreneurs. Revenue is generated through management fees and performance fees typical of private investment funds, with fund terms offered to qualified investors through Confidential Offering Circulars or Private Offering Memoranda. The team of approximately 15 includes PhD scientists, former investment bankers, biotech operators, and dedicated legal and finance functions, and the firm maintains deep operational involvement through board seats and embedded operating partners at portfolio companies such as AnaptysBio, Zymeworks, Lakefront Biotherapeutics, Actio Biosciences, and ReCode Therapeutics. Distribution is driven entirely by direct professional relationships and co-investor syndication rather than traditional sales channels.
EcoR1 Capital firmographics
Firmographics- Name
- EcoR1 Capital
- Legal name
- EcoR1 Capital, LLC
- Website
- https://ecor1cap.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- EcoR1 Capital is a privately held, biotech-focused investment advisory firm founded in 2013 in San Francisco that invests across all stages of drug research and development, managing a portfolio of 60–70+ biotechnology companies for qualified investors via management and performance fees.
- Ownership category
- akta.pro rank
EcoR1 Capital industry classification
Industry- Product category
- Biotechnology Investment Management
- NAICS
- Funds, Trusts, and Other Financial Vehicles (525), Other Investment Pools and Funds (5259)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Sustainable Private Markets (Impact PE/VC, Private Credit, Infrastructure) (FSAAALAG)
Keywords
Where EcoR1 Capital is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
EcoR1 Capital business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- Investment Management Fees: Generates revenue through management fees and performance fees from funds managed, typical of investment advisory firms
Go-to-market motion1 record
Marketing channels2 records
EcoR1 Capital product offering
Product offeringCore offering
EcoR1 Capital, LLC is a biotech-focused investment advisory firm that manages private funds deploying capital into biotechnology companies at all stages of research and development. The firm invests in public and private life sciences companies across oncology, immunology, genetic diseases, and other therapeutic areas, providing both capital and strategic partnership through long-term relationships with biotech entrepreneurs.
Product overview
EcoR1 Capital LLC is a biotech-focused investment advisory firm established in 2013 that invests in companies at all stages of research and development. The firm does not offer a unified technology product platform or modules — rather, it provides investment management services and strategic partnership to biotechnology companies through its venture portfolio. The company's core offering is its investment expertise and capital deployment across a portfolio of approximately 70+ biotech companies, as evidenced by their portfolio page listing companies including Accent Therapeutics, Actio Biosciences, Affinia, Affinivax, Aktis Oncology, AlloVir, Amagma, Anagin, Arcus, Artiva, Ashvattha, Atara, Atreca, Attovia, Atyr, Avidity, BridgeBio, Cellares, Centessa, Clementia, Codiak, Collegium, Denali, Dewpoint, Diagonal Therapeutics, Editas, Eikon, ElevateBio, Epikast, Flex, Freenome, Gossamer Bio, Intellia, Kezar, KindredBio, Kronos Bio, Kumquat, Kura, Magenta, Metacrine, Morphic, Morphimmune, Nabriva, Naurex, Neogene, Neurogene, Nikang, Notch, Nurix, Nuvation, Omniox, ORIC, Paratus, Pellepharm, Peloton, Prevail, ReCode, Relay, Rubius, Sage, Scholar Rock, Scorpion, Shattuck, Silverback, Syndax, Tectonic, Terremoto, Unity, Zapprx, and others.
Differentiator
Problem solved
Functional benefit
Products and services
- Biotech Investment Management Services Active management of private investment funds that deploy capital into public and private biotechnology companies across all stages of research and development, spanning oncology, immunology, genetic diseases, and other therapeutic areas. Provides both capital and long-term strategic partnership to biotech entrepreneurs, offered to qualified limited partners through Confidential Offering Circulars or Private Offering Memoranda.
Companies that use EcoR1 Capital
Customer profileIdeal customer profiles2 records
EcoR1 Capital technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
EcoR1 Capital partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- ZymeworkscoreDr. Adam Schayowitz serves as Acting Chief Development Officer at Zymeworks while continuing to serve as Operating Partner at EcoR1 Capital, demonstrating direct operational involvement with portfolio company.
Scale indicators4 records
Recent moves6 records
Expansion highlights4 records
EcoR1 Capital competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
EcoR1 Capital social profiles
Digital presenceEcoR1 Capital financial estimates
Financial estimateRevenue estimate
Valuation estimate
EcoR1 Capital leadership team
Management profileNumber of profiles
Profiles15 records
EcoR1 Capital funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EcoR1 Capital M&A and investment
M&A and investmentM&A
Investments145 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EcoR1 Capital
What does EcoR1 Capital do?
EcoR1 Capital, LLC is a biotech-focused investment advisory firm that manages private funds deploying capital into biotechnology companies at all stages of research and development. The firm invests in public and private life sciences companies across oncology, immunology, genetic diseases, and other therapeutic areas, providing both capital and strategic partnership through long-term relationships with biotech entrepreneurs.
Is EcoR1 Capital a public or private company?
EcoR1 Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was EcoR1 Capital founded?
EcoR1 Capital was founded in 2013. It employs 11 to 50 people.
Where is EcoR1 Capital based?
EcoR1 Capital is headquartered in San Francisco, United States, in the North America region.
How does EcoR1 Capital make money?
One revenue line is on record: investment Management Fees.
Does EcoR1 Capital have an API?
No public API is recorded for EcoR1 Capital.
What industry is EcoR1 Capital in?
EcoR1 Capital's product category is Biotechnology Investment Management. Its primary akta.pro industry code is FSAAALAG, Sustainable Private Markets (Impact PE/VC, Private Credit, Infrastructure). Its NAICS code is 525 and its SIC code is 6282.